Pain Detecting and Analgesic Stimulating Device on Low Back Pain
2016年1月8日 更新者:Jo Nijs、Vrije Universiteit Brussel
The Effects of a Pain Detecting and Analgesic Stimulating Device on Low Back Pain Patients' Clinical Outcomes
Purpose of study is to test in a randomized controlled trial (RCT) the effects of the Nervomatrix device on various clinical outcomes of patients with low back pain, as well as its mechanisms of action.
調査の概要
詳細な説明
This will be a matched randomized-controlled trial - RCT.
Using random numbers from a random number generator, pairs of patients will be randomized to either the Nervomatrix stimulation (experimental group) or to sham stimulation (controls).
Matching of pairs will be done based on the baseline data of the primary outcomes - pain and disability, as well as on other treatments received.
研究の種類
介入
入学 (実際)
39
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
-
Brussel、ベルギー、1050
- Vrije Universiteit Brussel
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年~65年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- chronic low back pain persisting for at least 3 months
Exclusion Criteria:
- patho-anatomical diagnosis (such as fractures, tumors, rheumatic diseases and neurological diseases)
- initiated a new conventional therapy during the study period
- pregnant
- patients having a cardiac pacemaker, implanted defibrillator, or other implanted metallic or electronic device
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Stimulation
Patients will undergo 6 sessions, each including 20 minutes of stimulation.
These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain.
The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
|
The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back.
Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions.
Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
他の名前:
|
|
偽コンパレータ:sham stimulation
Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation).
These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
|
The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back.
Regions with low resistance are then selected for brief mechanical pressure.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The change in the amount of steps climbed during one minute
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
Stair climbing: Participants were asked to climb up and down 5 stairs for 1 minute, using the rail for support if required.
The total amount of steps climbed will be recorded
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The change in central sensitization inventory
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
Part A of 25 statements related to current health symptoms.
Each of these items is measured on a 5-point temporal Likert scale, with the following numeric rating scale: never (0), rarely (1), sometimes (2), often (3), and always (4).
A cumulative score ranges from 0 to 100.
Additionally information is collected in Part B on previously diagnosed central sensitivity syndromes and related conditions.
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
|
The change in Pain Catastrophizing Scale
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
will be used to assess pain catastrophizing.
It consists of 13 items describing different thoughts and feelings that individuals may experience when they are experiencing pain.
Items are scored on a 5-point scale, and total scores are counted by adding up all individual items scores.
Higher scores correspond to more severe catastrophic thoughts about pain.
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
|
The change in revised Illness perception questionnaire
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
will be used for assessing the patients' illness perceptions, as it is known that patients with maladaptive illness perceptions (e.g.
expecting that their back problem will last for a long time, or holding weak beliefs in the controllability of their back problem) are more likely to have poor clinical outcomes 6 months after they consulted their physician
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
|
The change in average pain intensity
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
average pain rating in the last seven days using a 100 mm Visual Analogue Scale (VAS)
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
|
The change in Quebec Back Pain Disability Scale
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
This questionnaire consists of 20 activity related questions which the patient has to score on a six points scale (0= no; 5= not capable to perform the activity).
The total score represents a percentage of functional limitations the patient experiences during daily life.
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
|
The change in Tampa Scale of Kinesiophobia
時間枠:measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
Tampa Scale of Kinesiophobia is a 17-item questionnaire developed to measure the fear of movement and (re)injury.
Each item is scored on a four-point Likert scale ranging from "strongly disagree" [1] to "strongly agree" [4].
Ratings are added up to give a total score ranging from 17-68 points, with the higher values reflecting greater fear of (re)injury
|
measured prior to the first treatment session (baseline) and immediately following the 6th treatment session (after three weeks)
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始
2013年12月1日
一次修了 (実際)
2014年12月1日
研究の完了 (実際)
2015年2月1日
試験登録日
最初に提出
2013年12月13日
QC基準を満たした最初の提出物
2014年10月2日
最初の投稿 (見積もり)
2014年10月3日
学習記録の更新
投稿された最後の更新 (見積もり)
2016年1月12日
QC基準を満たした最後の更新が送信されました
2016年1月8日
最終確認日
2016年1月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。